Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence



Rating:

Share or cite this content

Citations should be made in the following way:
K. Kostikas (Ioannina, Greece), H. A M Kerstjens (Groningen, Netherlands), J. F Maspero (Buenos Aires, Argentina), K. R Chapman (Toronto, Canada), R. N Van Zyl-Smit (Cape Town, South Africa), M. Hosoe (Basel, Switzerland), A. Tanase (Basel, Switzerland), A. Pethe (East Hanover, United States of America), I. Kottakis (Basel, Switzerland), P. D'Andrea (East Hanover, United States of America). Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) improves lung function and reduces exacerbations in patients with asthma, independent of baseline airflow limitation: Results from IRIDIUM study. 3392

Member's Comments

No comment yet.

Related content which might interest you: Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept study Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) in patients with moderate COPD: Results from the CRYSTAL study Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Indacaterol/glycopyrronium (IND/GLY) improves lung function irrespective of gender baseline differences in patients with COPD: A pooled analysis from the IGNITE Program Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Combined effects of lung function, blood gases and kidney function on the exacerbation risk in stable COPD: Results from the German COSYCONET cohort. Source: International Congress 2019 – Lung function evaluation and prognosis of airway diseases Year: 2019 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 COPD: problems in diagnosis and measurement Source: Eur Respir J 2003; 21: 4S-12S Year: 2003 The main disease-related cost drivers in COPD: impaired lung function and exacerbations Source: Eur Respir J 2003; 22: Suppl. 45, 216s Year: 2003 Impact of age-related comorbidities on the risk of COPD exacerbations in subjects with severe airflow limitation: A pan-European study Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Among respiratory symptoms, wheeze associates most strongly with impaired lung function in adults with asthma - A long-term prospective cohort study Source: Virtual Congress 2021 – Asthma burden and management I Year: 2021 Do all COPD patients present irreversible airflow limitation? Source: Annual Congress 2013 –Expiration, exhalation and exhaustion: measures of dynamic volumes, breath analysis and respiratory muscles Year: 2013 Indacaterol/glycopyrronium (IND/GLY) improves lung function, health status and rescue medication use vs salmeterol/fluticasone (SFC) independent of symptom response: The FLAME study Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017 Value of measuring SGRQ at stable phase of COPD to predict the timing and deterioration associated with next exacerbation: the MOSAIC study Source: Eur Respir J 2004; 24: Suppl. 48, 240s Year: 2004 Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma Source: ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019 Year: 2020 QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013